![]() |
![]() |
Legal status
Patent in force
(51) | INT.CL. | C07D 498/04 | (2006.01) |
C07D 513/04 | (2006.01) | ||
A61K 31/437 | (2006.01) | ||
A61P 35/00 | (2006.01) |
(11) | Number of the document | 3094329 |
(13) | Kind of document | T |
(96) | European patent application number | 15735499.4 |
Date of filing the European patent application | 2015-01-12 | |
(97) | Date of publication of the European application | 2016-11-23 |
(45) | Date of publication and mention of the grant of the patent | 2018-09-26 |
(46) | Date of publication of the claims translation | 2018-11-26 |
(86) | Number | PCT/IB2015/050217 |
Date | 2015-01-12 |
(87) | Number | WO 2015/104688 |
Date | 2015-07-16 |
(30) | Number | Date | Country code |
158CH2014 | 2014-01-13 | IN | |
3000CH2014 | 2014-06-20 | IN |
(72) |
GUMMADI, Venkateshwar, Rao, IN
SAMAJDAR, Susanta, IN
|
(73) |
Aurigene Oncology Limited ,
39-40 KIADB Industrial Area
Electronic City Phase II
Hosur Road, Bangalore 560100,
IN
|
(74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
(54) | Bicikliniai heterociklilo dariniai kaip IRAK4 inhibitoriai |
BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS |
Payment date | Validity (years) | Amount | |
2024-12-18 | 11 | 289.00 EUR |
2026-01-12 |